
How non-traditional investors fuel up-and-coming biotechs when VC funding dries up
When times are tight, creative approaches reign supreme. For the biotech industry, which has seen several years of difficult financing, smaller companies have found it especially challenging to gain the runway they need to carry drug candidates through the …